Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Frontotemporal dementia (FTD) is a pathologically heterogeneous group of presenile neurodegenerative disorders, with or without the deposition of hyperphosphorylated tau protein in affected brain regions. Mutations in the tau gene have been found in the familial form of FTD, linked to chromosome 17q21-22, showing a spectrum of tauopathy. Objective To evaluate levels of total tau, phosphorylated tau 181 (Ptau-181), and amyloid-beta1-42 in the cerebrospinal fluid (CSF) of patients with FTD, with special emphasis on FTD due to tau mutations.

What this study adds

Evidence grade: Moderate

This is a case-control study of 18 participants. This case-control study measured total tau, phosphorylated tau 181, and amyloid-beta1-42 in cerebrospinal fluid of patients with frontotemporal dementia, including cases due to tau mutations. It is about fluid markers in frontotemporal dementia, not about treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rosso, S. M., van Herpen, E., Pijnenburg, Y. A., Schoonenboom, N. S., Scheltens, P., Heutink, P., et al. (2003). Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Archives of neurology. https://doi.org/10.1001/archneur.60.9.1209

Vancouver

Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Archives of neurology. 2003. doi:10.1001/archneur.60.9.1209. PMID: 12975285.

BibTeX

@article{rosso2003-12975285,
  author  = {Rosso, S. M. and van Herpen, E. and Pijnenburg, Y. A. and Schoonenboom, N. S. and Scheltens, P. and Heutink, P. and van Swieten, J. C.},
  title   = {{Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations}},
  journal = {Archives of neurology},
  year    = {2003},
  doi     = {10.1001/archneur.60.9.1209},
  pmid    = {12975285},
  url     = {https://doi.org/10.1001/archneur.60.9.1209}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This case-control study measured total tau, phosphorylated tau 181, and amyloid-beta1-42 in cerebrospinal fluid of patients with frontotemporal dementia, including cases due to tau mutations. It is about fluid markers in frontotemporal dementia, not about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 6 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 2 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a peer-reviewed journal, and it is a case-control study. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of neurology)
Journal's citation record 3 / 4 Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2003 — older than 20 years, still counted
Sample size 1 / 4 18 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 77 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.1 citations a year over 25 year(s) since 2003
Impact for its field and year 2 / 6 Cited 2.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author John Cornelis Van Swieten: h-index 104 (OpenAlex, whole career)
Institution's track record 1 / 3 Erasmus MC: institution h-index 1,321 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 12975285)
Free to read 0 / 2 Behind a paywall — scores zero
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →